A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Phase 3Active Not RecruitingNCT06260163

Janssen Research & Development, LLC112 enrolled

Overview

The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

112

Conditions

Colitis, Ulcerative

Interventions

Guselkumab SubcutaneousDRUG

Guselkumab will be administered subcutaneously.

Guselkumab IntravenousDRUG

Guselkumab will be administered intravenously.

Eligibility

Sex: ALLMin age: 2 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Weight greater than or equal to (\>=) 10 kilogram (kg) at the time of consent for screening * A pathology report to support a documented diagnosis of Ulcerative Colitis (UC) must be available in the source documents. There is no maximum duration for which a participant needs to be diagnosed with UC. If the pathology report to support a documented diagnosis of UC is not available in the source documents, the screening endoscopy with biopsies (obtained within 3 weeks before first study intervention administration) needs to support the diagnosis of UC. * Moderately to severely active UC, defined by a baseline modified Mayo (without physician's global assessment) score of 5 through 9 inclusive, with a screening Mayo endoscopy subscore \>= 2 as determined by a central review of the video of the endoscopy * Medically stable based on physical examination, medical history, and vital signs, performed at screening. Any abnormalities must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and acknowledged by the investigator * Participants must have had an inadequate response and/or intolerance to biologic therapy and/or conventional therapies or be dependent upon corticosteroids Exclusion Criteria: * Have UC limited to the rectum only or to less than (\<) 20 centimeter of the colon * Presence of a stoma * Has had any kind of bowel resection within 6 months or any other intra-abdominal surgery within 3 months of baseline * Have severe colitis or have evidence of Crohn's Disease (CD)

Locations (61)

Outcomes

Primary Outcomes

Percentage of Participants with Clinical Remission at Week 56

Percentage of participants with clinical remission as assessed by modified Mayo score at Week 56 among participants who were induction responders will be reported. Clinical remission per modified Mayo score is defined as a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline.

Time frame: Week 56

Secondary Outcomes

Percentage of Participants with Clinical Response at Week 12

Percentage of participants with clinical response as assessed by modified Mayo score at Week 12 will be reported. Modified Mayo score is a 3-component (stool frequency, rectal bleeding, and endoscopy subscores) assessment and does not include the physician's global assessment. A decrease from baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent and \>= 2 points, with either a decrease from baseline in the rectal bleeding subscore of \>= 1 or a rectal bleeding subscore of 0 or 1.

Time frame: Week 12

Percentage of Participants with Clinical Remission at Week 12

Percentage of participants with clinical remission at Week 12 as assessed by modified Mayo score will be reported. Clinical remission per modified Mayo score is defined as a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline.

Time frame: Week 12

Percentage of Participants With Pediatric Ulcerative Colitis Activity Index (PUCAI) Remission at Week 12

Percentage of participants with PUCAI remission at Week 12 will be reported. It comprises 6 scales and ranges between 0 and 85 points. The scales are abdominal pain, rectal bleeding, stool consistency, number of stools, nocturnal bowel movement, and activity level. The PUCAI score is calculated as the sum of the 6 subscores. A PUCAI score of less than (\<) 10 indicates remission.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Children's Hospital Oakland

Oakland, California, United States

Riley Hospital for Children

Indianapolis, Indiana, United States

NYU Langone Health

Lake Success, New York, United States

The Kids Research Institute Australia on behalf of the Centre for Child Health Research

Nedlands, Australia

Mater Hospital Brisbane Inflammatory Bowel Diseases

South Brisbane, Australia

The Children's Hospital at Westmead

Westmead, Australia

CHU Charleroi Chimay

Charleroi, Belgium

UZ Gent

Ghent, Belgium

UZ Brussel

Jette, Belgium

UZ Leuven

Leuven, Belgium

...and 51 more locations

Percentage of Participants with Symptomatic Remission at Week 12

Percentage of participants with symptomatic remission at Week 12 will be reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline.

Time frame: Week 12

United States: Percentage of Participants with Endoscopic Improvement at Week 12

Percentage of participants with endoscopic improvement as assessed by Mayo endoscopy subscore at Week 12 will be reported. Endoscopic improvement is defined as the Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.

Time frame: Week 12

European Union: Percentage of Participants with Endoscopic Healing at Week 12

Percentage of participants with endoscopic healing as assessed by Mayo endoscopy subscore at Week 12 will be reported. Endoscopic healing is defined as the Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.

Time frame: Week 12

Percentage of Participants with Clinical Response at Week 56

Percentage of participants with clinical response as assessed by modified Mayo score at Week 56 will be reported. Modified Mayo score is a 3-component (stool frequency, rectal bleeding, and endoscopy subscores) assessment and does not include the physician's global assessment. A decrease from baseline in the modified Mayo score by \>= 30 percent and \>= 2 points, with either a decrease from baseline in the rectal bleeding subscore of \>= 1 or a rectal bleeding subscore of 0 or 1.

Time frame: Week 56

Percentage of Participants With PUCAI Remission at Week 56

Percentage of participants with PUCAI remission at Week 56 will be reported. PUCAI comprises of 6 scales and ranges between 0 and 85 points. The scales are: abdominal pain, rectal bleeding, stool consistency, number of stools, nocturnal bowel movement, and activity level. The PUCAI score is calculated as the sum of the 6 subscores. A PUCAI score of less than (\<) 10 indicates remission.

Time frame: Week 56

Percentage of Participants with Symptomatic Remission at Week 56

Percentage of participants with symptomatic remission at Week 56 will be reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline.

Time frame: Week 56

Percentage of Participants with Symptomatic Remission at Week 56 Among Participants who had Symptomatic Remission at Week 12

Percentage of participants with symptomatic remission at Week 56 among participants who had symptomatic remission at Week 12 will be reported. Symptomatic remission score is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline.

Time frame: Week 56

United States: Percentage of Participants With Endoscopic Improvement at Week 56

Percentage of participants with endoscopic improvement as assessed by Mayo endoscopy subscore at Week 56 will be reported. Endoscopic improvement is defined as the Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.

Time frame: Week 56

European Union: Percentage of Participants With Endoscopic Healing at Week 56

Percentage of participants with endoscopic healing as assessed by Mayo endoscopy subscore at Week 56 will be reported. Endoscopic healing is defined as the Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.

Time frame: Week 56

Percentage of Participants Who Achieve Endoscopic Normalization at Week 56

Percentage of participants who achieve endoscopic normalization with an endoscopy subscore of 0 at Week 56 will be reported.

Time frame: Week 56

Percentage of Participants Histo-endoscopic Mucosal Improvement at Week 56

Percentage of participants histo-endoscopic mucosal healing per endoscopy subscore and histologic improvement at Week 56 will be reported. Histologic-endoscopic mucosal healing is defined as achieving a combination of histologic improvement and endoscopic improvement (US) or endoscopic healing (EU) (endoscopy subscore of 0 or 1).

Time frame: Week 56

Percentage of Participants with Corticosteroid-free Clinical Remission at Week 56

Percentage of participants with corticosteroid-free clinical remission at Week 56 will be reported. Corticosteroid free clinical remission is defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline (Week 0), and not receiving corticosteroids for at least 8 weeks prior to Week 56

Time frame: Week 56

Serum Concentration of Guselkumab During Induction Phase

Serum samples will be analyzed to determine concentrations of guselkumab overtime.

Time frame: From Week 0 to Week 12

Serum Concentration of Guselkumab During Maintenance Phase

Serum samples will be analyzed to determine concentrations of guselkumab over time.

Time frame: From Week 12 to Week 56

Number of Participants with Incidence of Anti-guselkumab Antibodies

Number of participants with anti-guselkumab antibodies for all study treatment regimens will be assessed.

Time frame: Up to Week 68

Percentage of Participants with Adverse Events (AEs)

Percentage of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Time frame: Up to Week 68

Percentage of Participants with Serious Adverse Events (SAEs)

Percentage of participants with SAEs will be reported. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly.

Time frame: Up to Week 68

Percentage of Participants with AEs Leading to Discontinuation of Study Intervention

Percentage of participants with AEs leading to discontinuation of study intervention will be reported.

Time frame: Up to Week 68